Description
α2-Agonist
Indications: Standing restraint, providing both analgesia and sedation with sedation lasting longer
than analgesia.
Peak effect occurs approximately 2 to 5 and 15 to 30 minutes after intravenous and intramuscular administration, respectively.
Side effects: Bradycardia, second-degree atrioventricular block, biphasic hypertension followed by
hypotension, increased urine production, moderate hyperglycemia, sweating, and decreased gastrointestinal motility.
Contra indications: The safety has not been established during pregnancy. Do not use in mares in the last month of pregnancy.
Dosage:
Equine Bolus: 0.01 mg/kg IV / IM
Supplemental IV doses can be given one-quarter to one-half of the initial dose.
CRI: 0.01–0.04 mg/kg/h
